3.03
0.11 (3.60%)
| Penutupan Terdahulu | 2.92 |
| Buka | 2.99 |
| Jumlah Dagangan | 130,427 |
| Purata Dagangan (3B) | 1,270,601 |
| Modal Pasaran | 327,744,352 |
| Harga / Jualan (P/S) | 19.85 |
| Harga / Buku (P/B) | 2.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | -1,222.27% |
| EPS Cair (TTM) | -1.59 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -39.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.72% |
| Nisbah Semasa (MRQ) | 5.06 |
| Aliran Tunai Operasi (OCF TTM) | -12.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.41 M |
| Pulangan Atas Aset (ROA TTM) | -18.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -91.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Aclaris Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.88 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.69% |
| % Dimiliki oleh Institusi | 88.24% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bml Capital Management, Llc | 30 Sep 2025 | 14,250,000 |
| Vivo Capital, Llc | 30 Sep 2025 | 8,888,888 |
| Rock Springs Capital Management Lp | 30 Sep 2025 | 4,609,309 |
| Decheng Capital Llc | 30 Sep 2025 | 4,041,736 |
| Palo Alto Investors Lp | 30 Sep 2025 | 1,566,840 |
| Julat 52 Minggu | ||
| Median | 16.00 (428.93%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Oct 2025 | 16.00 (428.93%) | Beli | 2.01 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DAVIS HUGH M. | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| DAVIS HUGH M. | Pegawai | 02 Dec 2025 | Pelaksanaan pilihan | 26,750 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |